Literature DB >> 30705850

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

Alessandro Inno1, Anna Stagno1,2, Stefania Gori1.   

Abstract

Entities:  

Year:  2018        PMID： 30705850      PMCID： PMC6328697          DOI： 10.21037/tlcr.2018.11.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

1.  Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

Authors:  Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Nicole Fer; Dmitriy Sonkin; Gurmeet Kaur; Anne Monks; Shakun Malik; Joel Morris; Beverly A Teicher
Journal:  J Natl Cancer Inst       Date:  2016-05-31       Impact factor: 13.506

Review 2.  Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

Authors:  Antonio Rossi; Massimo Di Maio; Paolo Chiodini; Robin Michael Rudd; Hiroaki Okamoto; Dimosthenis Vasilios Skarlos; Martin Früh; Wendi Qian; Tomohide Tamura; Epaminondas Samantas; Taro Shibata; Francesco Perrone; Ciro Gallo; Cesare Gridelli; Olga Martelli; Siow-Ming Lee
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

3.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Authors:  Nasser Hanna; Paul A Bunn; Corey Langer; Lawrence Einhorn; Troy Guthrie; Thaddeus Beck; Rafat Ansari; Peter Ellis; Michael Byrne; Mark Morrison; Subramanian Hariharan; Benjamin Wang; Alan Sandler
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

4.  Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

Authors:  Harvey B Niell; James E Herndon; Antonius A Miller; Dorothy M Watson; Alan B Sandler; Karen Kelly; Randolph S Marks; Micheal C Perry; Rafat H Ansari; Grefory Otterson; John Ellerton; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2005-06-01       Impact factor: 44.544

Review 5.  Small cell lung cancer: where do we go from here?

Authors:  Lauren Averett Byers; Charles M Rudin
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

6.  Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Authors:  M Catherine Pietanza; Kyuichi Kadota; Kety Huberman; Camelia S Sima; John J Fiore; Dyana K Sumner; William D Travis; Adriana Heguy; Michelle S Ginsberg; Andrei I Holodny; Timothy A Chan; Naiyer A Rizvi; Christopher G Azzoli; Gregory J Riely; Mark G Kris; Lee M Krug
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

7.  PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.

Authors:  Benjamin H Lok; Eric E Gardner; Valentina E Schneeberger; Andy Ni; Patrice Desmeules; Natasha Rekhtman; Elisa de Stanchina; Beverly A Teicher; Nadeem Riaz; Simon N Powell; John T Poirier; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2016-07-20       Impact factor: 12.531

8.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

9.  Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Authors:  Charles M Rudin; M Catherine Pietanza; Todd M Bauer; Neal Ready; Daniel Morgensztern; Bonnie S Glisson; Lauren A Byers; Melissa L Johnson; Howard A Burris; Francisco Robert; Tae H Han; Sheila Bheddah; Noah Theiss; Sky Watson; Deepan Mathur; Bharathi Vennapusa; Hany Zayed; Satwant Lally; Donald K Strickland; Ramaswamy Govindan; Scott J Dylla; Stanford L Peng; David R Spigel
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

10.  Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients.

Authors:  Nobuyuki Horita; Masaki Yamamoto; Takashi Sato; Toshinori Tsukahara; Hideyuki Nagakura; Ken Tashiro; Yuji Shibata; Hiroki Watanabe; Kenjiro Nagai; Miyo Inoue; Kentaro Nakashima; Ryota Ushio; Masaharu Shinkai; Makoto Kudo; Takeshi Kaneko
Journal:  Sci Rep       Date:  2015-10-21       Impact factor: 4.379
View more
  3 in total

Review 1.  Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.

Authors:  Diana Saleiro; Leonidas C Platanias
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

Review 2.  Molecular profiles of small cell lung cancer subtypes: therapeutic implications.

Authors:  Anna Schwendenwein; Zsolt Megyesfalvi; Nandor Barany; Zsuzsanna Valko; Edina Bugyik; Christian Lang; Bence Ferencz; Sandor Paku; Andras Lantos; Janos Fillinger; Melinda Rezeli; Gyorgy Marko-Varga; Krisztina Bogos; Gabriella Galffy; Ferenc Renyi-Vamos; Mir Alireza Hoda; Walter Klepetko; Konrad Hoetzenecker; Viktoria Laszlo; Balazs Dome
Journal:  Mol Ther Oncolytics       Date:  2021-02-06       Impact factor: 7.200

Review 3.  Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance.

Authors:  Adnin Ashrafi; Zakia Akter; Pouya Modareszadeh; Parsa Modareszadeh; Eranda Berisha; Parinaz Sadat Alemi; Maria Del Carmen Chacon Castro; Alexander R Deese; Li Zhang
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.